Abstract: The invention relates to haptoglobin or a nucleic acid encoding haptoglobin for use in treating or preventing of exaggerated erectile response and/or preventing permanent erectile dysfunction. In addition, the invention relates a pharmaceutical composition for use in treating or preventing exaggerated erectile response and/or preventing permanent erectile dysfunction, wherein the pharmaceutical composition comprises an adeno-associated viral (AAV) vector with a transgene encoding a haptoglobin gene. The exaggerated erectile response may be priapism, for example priapism associated with sickle cell disease (SCD).

Abstract: The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and/or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to an expression system for producing a recombinant haptoglobin (Hp) beta chain, or a haemoglobin-binding fragment thereof, recombinant Hp molecules and uses thereof for treating and/or preventing a condition associated with cell-free haemoglobin (Hb).

Abstract: The invention relates to methods for determining the concentration of an analyte in a sample obtained from processing of blood-derived plasma, the method comprising applying a light source in the near-infrared spectrum to a test sample obtained from processing of blood-derived plasma; measuring reflectance, transmission or transflectance of the test sample over a range of near-infrared wavelengths, thereby generating test wavelength spectra, comparing the test wavelength spectra with reference wavelength spectra obtained from reference samples having known concentrations of the analyte, to determine the concentration of the analyte in the sample. The invention also relates to the development of a multivariate model for use in determining the concentration of an analyte, for example, total protein or alcohol (e.g. ethanol).

Abstract: The present invention relates generally to a stable liquid formulation of purified hemopexin comprising: (a) a hemopexin content of at least 50 mg/mL; (b) at least 15 mM phosphate buffer; (c) a pH from 5.8 to 8; and (d) at least 50 mM sodium chloride; and uses thereof.

Abstract: The present invention relates to an immunoglobulin therapy. In particular, an immunoglobulin therapy for treating CIDP with non-axonal damage or mild axonal damage is provided.

Abstract: The present invention pertains to a pharmaceutical product comprising a polyclonal immunoglobulin solution in a pre-filled polymer syringe in secondary packaging comprising an oxygen scavenger.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to improved industrial scale processes for removing metal cations, such as copper, from blood plasma derived albumin products and pharmaceutical compositions derived therefrom. The albumin sample is contacted with a ligand for binding to or sequestering the metal cations, said ligand is a chelating agent, most preferably a biodegradable chelating agent, or a chelating resin, most preferably a cation-exchange chelating resin.

Abstract: The present invention pertains to a pharmaceutical product comprising a polyclonal immunoglobulin solution in a pre-filled polymer syringe in secondary packaging comprising an oxygen scavenger.

Abstract: The invention relates to a method for the purification of immunoglobulin and/or albumin from a sample of plasma, the method comprising mixing a sample of plasma with a medium chain fatty acid, and recovering the soluble immunoglobulin from the mixture.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to a method and a system of extracting a protein with high yield from a protein-comprising precipitate, in particular immunoglobulin, from human or non-human origins, such as blood plasma.

Abstract: The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and/or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).

Abstract: The invention relates to methods for generating an aerosol by nebulization of a composition comprising polyclonal immunoglobulin (Ig). The selection of an efficient membrane nebulizer and a composition optimized for nebulization with such membrane nebulizer results in a particularly efficient method of generating an aerosol for administration of Ig to the respiratory tract.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to a method and a system of extracting a protein with high yield from a protein-comprising precipitate, in particular immunoglobulin, from human or non-human origins, such as blood plasma.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to a method and a system of extracting a protein with high yield from a protein-comprising precipitate, in particular immunoglobulin, from human or non-human origins, such as blood plasma.